<DOC>
	<DOCNO>NCT01524809</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate steady state pharmacokinetics biphasic insulin aspart 30 biphasic insulin aspart 70 subject type 1 diabetes .</brief_summary>
	<brief_title>Pharmacokinetics Biphasic Insulin Aspart 30 70 Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 1 diabetes least 12 month Currently multiple dose insulin regimen HbA1c maximum 12.0 % BMI ( body mass index ) 35 kg/m^2 Able willing perform selfblood glucose monitoring ( SBGM ) Treatment insulin aspart within last 14 day prior trial The receipt investigational drug within last 30 day prior trial Total daily insulin dose least 1.8 U/kg A history drug abuse alcohol dependence within last 5 year Impaired hepatic function Impaired renal function Blood donation within last nine week haemoglobin low reference limit accord local laboratory Cardiac disease Severe , uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>